To test the hypothesis that IDH-mutant glioma cells are more sensitive to HDAC inhibition, we generated glioma cell lines that expressed mtIDH1 and tested for sensitivity to HDAC inhibition, including with the pan-HDACi belinostat. This evidence concerns the gene HDAC9 and central nervous system cancer.